Literature DB >> 31366280

Current state of melanoma diagnosis and treatment.

Lauren E Davis1, Sara C Shalin2, Alan J Tackett1.   

Abstract

Melanoma is the deadliest form of skin cancer. In the early stages, melanoma can be treated successfully with surgery alone and survival rates are high, but after metastasis survival rates drop significantly. Therefore, early and correct diagnosis is key for ensuring patients have the best possible prognosis. Melanoma misdiagnosis accounts for more pathology and dermatology malpractice claims than any cancer other than breast cancer, as an early misdiagnosis can significantly reduce a patient's chances of survival. As far as treatment for metastatic melanoma goes, there have been several new drugs developed over the last 10 years that have greatly improved the prognosis of patients with metastatic melanoma, however, a majority of patients do not show a lasting response to these treatments. Thus, new biomarkers and drug targets are needed to improve the accuracy of melanoma diagnosis and treatment. This article will discuss the major advancements of melanoma diagnosis and treatment from antiquity to the present day.

Entities:  

Keywords:  Melanoma; diagnosis; epigenetics; immunohistochemistry; immunotherapy; treatment

Mesh:

Substances:

Year:  2019        PMID: 31366280      PMCID: PMC6804807          DOI: 10.1080/15384047.2019.1640032

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  117 in total

1.  Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis.

Authors:  Chunying Li; Zhibin Hu; Zhensheng Liu; Li-E Wang; Sara S Strom; Jeffrey E Gershenwald; Jeffrey E Lee; Merrick I Ross; Paul F Mansfield; Janice N Cormier; Victor G Prieto; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12       Impact factor: 4.254

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

Review 3.  Malignant melanoma-The cradle of anti-neoplastic immunotherapy.

Authors:  Kristian M Koller; Wenge Wang; Todd D Schell; Eugene M Cozza; Kathleen M Kokolus; Rogerio I Neves; Heath B Mackley; Colette Pameijer; Anna Leung; Bryan Anderson; Carol A Mallon; Gavin Robertson; Joseph J Drabick
Journal:  Crit Rev Oncol Hematol       Date:  2016-05-07       Impact factor: 6.312

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma.

Authors:  M Prade; H Sancho-Garnier; J P Cesarini; A Cochran
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

Review 6.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

Review 7.  Use of immunohistochemistry in melanocytic lesions.

Authors:  Victor G Prieto; Christopher R Shea
Journal:  J Cutan Pathol       Date:  2008-11       Impact factor: 1.587

8.  Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.

Authors:  Inga-Marie Schaefer; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-11-20       Impact factor: 7.842

Review 9.  Resistant mechanisms to BRAF inhibitors in melanoma.

Authors:  José Luís Manzano; Laura Layos; Cristina Bugés; María de Los Llanos Gil; Laia Vila; Eva Martínez-Balibrea; Anna Martínez-Cardús
Journal:  Ann Transl Med       Date:  2016-06

10.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Sandrine Duigou; Stéphanie Bouvier; Marc De Braekeleer; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

View more
  100 in total

1.  Establishment and validation of an autophagy-related prognostic signature for survival predicting in cutaneous melanoma.

Authors:  Hongjun Fei; Xiongming Chen
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  Cardiotoxicity of Systemic Melanoma Treatments.

Authors:  Neha Mukunda; Srilakshmi Vallabhaneni; Benedicte Lefebvre; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

3.  HYPONATREMIA - A COMMON PROBLEM WITH AN UNCOMMON ETIOLOGY.

Authors:  C M Tîrziu; I M Cristea
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

4.  Localised light delivery on melanoma cells using optical microneedles.

Authors:  Xiaobin Wu; Jongho Park; Siu Yu A Chow; Maria Carmelita Z Kasuya; Yoshiho Ikeuchi; Beomjoon Kim
Journal:  Biomed Opt Express       Date:  2022-01-31       Impact factor: 3.732

5.  Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma.

Authors:  Ling Xue; Pingfan Wu; Xiaowen Zhao; Xiaojie Jin; Jingjing Wang; Yuxiang Shi; Xiaojing Yang; Yali She; Yaling Li; Changtian Li
Journal:  Int J Gen Med       Date:  2021-10-08

6.  A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.

Authors:  Surachet Imlimthan; You Cheng Khng; Outi Keinänen; Wenzhong Zhang; Anu J Airaksinen; Mauri A Kostiainen; Brian M Zeglis; Hélder A Santos; Mirkka Sarparanta
Journal:  Small       Date:  2021-03-18       Impact factor: 13.281

7.  LncRNA MIAT promotes the proliferation, migration, and invasion of melanoma cells through recruiting TCF12 and activating NFAT5.

Authors:  Fei Lu; Ying Song; Shuo Cui; Huafei Zhao; Yuhua Chen; Hao Du
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 8.  Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

Authors:  Stephanie McKenna; Lucía García-Gutiérrez
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

9.  Nomogram Incorporating the WNT/β-Catenin Signaling Pathway for Predicting the Survival of Cutaneous Melanoma.

Authors:  Yu-Xin Zhou; Xin Wang; De-Quan Pang; Ying-Man Wang; Jing Bai; Fei Tian; Duo Han; Shuwei Shi; Lei Hu
Journal:  Int J Gen Med       Date:  2021-06-23

10.  The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Authors:  Lazaro Hiram Betancourt; Jeovanis Gil; Aniel Sanchez; Viktória Doma; Magdalena Kuras; Jimmy Rodriguez Murillo; Erika Velasquez; Uğur Çakır; Yonghyo Kim; Yutaka Sugihara; Indira Pla Parada; Beáta Szeitz; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Jonatan Eriksson; Krzysztof Pawłowski; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Johan Malm; Runyu Hong; Peter Horvath; A Marcell Szász; József Tímár; Sarolta Kárpáti; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Quimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Leticia Szadai; István Balázs Németh; Henrik Ekedahl; David Fenyö; György Marko-Varga
Journal:  Clin Transl Med       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.